- 4 CPE Points: Singapore Breast Oncoplastic Surgery Symposium (SBOSS)
- 2 CPE Points: Oncology Nursing Session
- 6 CPE Points: Asia-Pacific Breast Cancer Summit (APBCS)
Avail up to 12 CPE Points
Accredited by Singapore Medical Council
APBCS over the years
ORGANIZING COMMITTEE
Shaheenah Dawood
Medical Oncologist, United Arab Emirates
Rebecca Dent
MEDICAL ONCOLOGIST, Singapore
Lee Soo Chin
MEDICAL ONCOLOGIST, Singapore
- Detailed interactive event agenda
- Personal custom agenda for specific attendees
- Attendees can save specific sessions to their personal agenda
- Live stream conference sessions, networking and interaction
- Questions can be asked live from anywhere
- Easily cycle between sessions, video, comments and Q&A
- Detailed interactive event agenda
- Personal custom agenda for specific attendees
- Attendees can save specific sessions to their personal agenda
- Live stream conference sessions, networking and interaction
- Questions can be asked live from anywhere
- Easily cycle between sessions, video, comments and Q&A
- Allow onsite and offsite participants to ask questions live
- All participants can ask and view questions anywhere in the world
- Questions are shown beneath your live streaming sessions
- Send live polls to onsite and offsite participants instantly
- All participants can respond to polls anywhere in the world
- Instant Messaging available between onsite and offsite participants
- Ability to filter between onsite and offsite participants
- Network and set up virtual face to face meetings with other users
- Instant Messaging available between onsite and offsite participants
- Ability to filter between onsite and offsite participants
- Network and set up virtual face to face meetings with other users
- Participants can connect via video call to the members of your team
Who Should Attend?
2022 Sponsors
Main Sponsors
Platinum Sponsors
Exhibitor
Supported by
Have cellular therapies finally made an impact on solid tumors?
Claudin18.2-specific CAR T cells in gastrointestinal cancers. Published in @Nature.
The ORR was 48.6%. (mostly gastric and pancreatic cancer).
👇🏽 👇🏽
https://www.nature.com/articles/s41591-022-01800-8?error=cookies_not_supported&code=57a1b21c-7ec4-4aa6-b758-5e1451db787f
Rasti and colleagues present an excellent overview of potentially targeting the PIK3CA pathway in HER2 positive Breast Cancer.
Almost 30% of patients with HER2 positive breast cancer have a PIK3CA mutation and multiple prospective trials to look forward…https://lnkd.in/eG5YpHQ3
Joensuu et al publish the 15 years overall survival results of adjuvant capecitabine in combination with anthracycline and docetaxel based chemo back bone in a high risk cohort of patients with early stage breast cancer. The investigators show an OS advan…https://lnkd.in/eiDgSneC
An excellent paper published in Clinical Cancer Research. Important study results included : 1. Across solid tumors that were tested for somatic mutations 3.6% had a pathogenic BRCA / PALB2 mutation , 2. Only 48% of these patients were tested for germline…https://lnkd.in/eQkgKsn4
